伏诺拉生联合标准四联疗法治疗Hp阳性胃食管反流病患者的效果  

Effects of Vonoprazan combined with standard quadruple therapy in treatment of Hp positive gastroesophageal reflux disease

作　　者：李连忠 LI Lianzhong(Mudan District Hospital of Traditional Chinese Medicine of Heze City,Heze 274000 Shandong,China)

机构地区：[1]菏泽市牡丹区中医医院,山东菏泽274000

出　　处：《中国民康医学》2024年第9期43-45,49,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察伏诺拉生联合标准四联疗法治疗幽门螺杆菌(Hp)阳性胃食管反流病患者的效果。方法:选取2021年2月至2023年3月该院收治的80例Hp阳性胃食管反流病患者进行前瞻性研究,按照随机数字表法将其分为研究组与对照组各40例。对照组采用标准四联疗法治疗,研究组在对照组基础上联合伏诺拉生治疗,比较两组临床疗效、Hp根除率及治疗前后食管括约肌静息压[食管上括约肌(UES)静息压、食管下括约肌(LES)静息压]水平、胃肠激素指标[胃蛋白酶原I(PGI)、胃泌素-17(G-17)]水平和胃肠黏膜屏障功能指标[二胺氧化酶(DAO)、D-乳酸、内毒素]水平。结果:研究组治疗总有效率为97.50%(39/40),高于对照组的77.50%(31/40),差异有统计学意义(P<0.05);研究组Hp根除率为87.50%(35/40),高于对照组的67.50%(27/40),差异有统计学意义(P<0.05);治疗后,两组USE静息压、LES静息压水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);两组PGI、G-17水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组DAO、D-乳酸、内毒素水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:伏诺拉生联合标准四联治疗Hp阳性胃食管反流病患者可提高临床疗效、Hp根除率、食管括约肌静息压水平,改善胃肠激素指标和胃肠黏膜屏障功能指标水平,其效果优于单纯标准四联疗法治疗。Objective:To observe effects of Vonoprazan combined with standard quadruple therapy in treatment of Helicobacter pylori(Hp)positive gastroesophageal reflux disease.Methods:A prospective study was conducted on 80 patients with Hp-positive gastroesophageal reflux disease admitted to this hospital from February 2021 to March 2023.According to the random number table method,they were divided into study group and control group,40 cases in each group.The control group was treated with standard quadruple therapy,while the study group was treated with Vonoprazan on the basis of that of the control group.The clinical efficacy,the Hp eradication rate,the esophageal sphincter resting pressure[upper esophageal sphincter(UES)resting pressure,lower esophageal sphincter(LES)resting pressure]levels,the gastrointestinal hormone index[pepsinogen I(PGI),gastrin-17(G-17)]levels,and the gastrointestinal mucosal barrier function index[diamine oxidase(DAO),D-lactic acid,endotoxin]levels were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the study group was 97.50%(39/40),which was higher than 77.50%(31/40)in the control group,and the difference was statistically significant(P<0.05).The eradication rate of Hp in the study group was 87.50%(35/40),which was higher than 67.50%(27/40)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the resting pressure levels of USE and LES in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of PGI and G-17 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of DAO,D-lactic acid and endotoxin in the two groups were lower than those before the treatment,those in the study group were lower than those in the

关 键 词：伏诺拉生 标准四联疗法 HP阳性 胃食管反流病 胃肠黏膜屏障 胃肠激素 不良反应 

分 类 号：R571[医药卫生—消化系统]